Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 205 of the 206 references it cites were found in a registry or an index; 68 of the 244 sources its claims cite were checked for support.
Abstract
Objective The aim was to develop clinical practice guidelines on hypertriglyceridemia. Participants The Task Force included a chair selected by The Endocrine Society Clinical Guidelines Subcommittee (CGS), five additional experts in the field, and a methodologist. The authors received no corporate funding or remuneration. Consensus process Consensus was guided by systematic reviews of evidence, e-mail discussion, conference calls, and one in-person meeting. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage, the Task Force incorporated changes in response to written comments. Conclusions The Task Force recommends that the diagnosis of hypertriglyceridemia be based on fasting levels, that mild and moderate hypertriglyceridemia (triglycerides of 150-999 mg/dl) be diagnosed to aid in the evaluation of cardiovascular risk, and that severe and very severe hypertriglyceridemia (triglycerides of > 1000 mg/dl) be considered a risk for pancreatitis. The Task Force also recommends that patients with hypertriglyceridemia be evaluated for secondary causes of hyperlipidemia and that subjects with primary hypertriglyceridemia be evaluated for family history of dyslipidemia and cardiovascular disease. The Task Force recommends that the treatment goal in patients with moderate hypertriglyceridemia be a non-high-density lipoprotein chole…
Overview
CoChat Summary
TL;DR
This Endocrine Society clinical practice guideline recommends evaluating and treating hypertriglyceridemia with fasting triglyceride measurement, secondary-cause workup, lifestyle therapy for mild-to-moderate elevations, and combined diet plus drug therapy for severe/very severe hypertriglyceridemia to prevent pancreatitis. It also concludes that triglycerides are associated with cardiovascular risk but whether they are causal remains uncertain.
Key findings
- The guideline recommends screening adults with a fasting lipid panel at least every 5 yr (1/QQEE), basing hypertriglyceridemia diagnosis on fasting rather than nonfasting triglycerides (1/QQQE), and against routine lipoprotein particle heterogeneity measurement (1/QQEE).
- It defines moderate hypertriglyceridemia as 200–999 mg/dl, severe as 1000–1999 mg/dl, and very severe as ≥2000 mg/dl; for severe/very severe hypertriglyceridemia (>1000 mg/dl), it recommends combining dietary fat and simple carbohydrate reduction with drug treatment to reduce pancreatitis risk (1/QQQQ), with fibrate as first-line for triglyceride-induced pancreatitis (1/QQQE).
- Lifestyle therapy is recommended initially for mild-to-moderate hypertriglyceridemia (1/QQEE); for moderate hypertriglyceridemia, the treatment goal is a non-HDL cholesterol level in agreement with NCEP ATP guidelines (1/QQEE); statins should not be used as monotherapy for severe or very severe hypertriglyceridemia but may be useful for moderate hypertriglyceridemia to modify cardiovascular risk (1/QQEE).
- In NHANES 1999–2004, 33% of nearly 6000 participants had serum triglycerides ≥150 mg/dl (42% among those aged ≥60 yr); about 14% had 150–200 mg/dl, 16% had 200–500 mg/dl, and about 2% had >500 mg/dl. Meta-analytic estimates included an adjusted odds ratio of 1.72 (95% CI, 1.56–1.90) for coronary heart disease comparing top vs bottom triglyceride tertiles, and an ERFC hazard ratio of 1.37 (95% CI, 1.31–1.42) after adjustment for nonlipid factors, reduced to 0.99 (95% CI, 0.94–1.05) after adjustment for HDL and non-HDL cholesterol.
Methods
- The Task Force followed the GRADE approach: strong recommendations use “we recommend” and number 1; weak recommendations use “we suggest” and number 2; evidence quality is denoted QEEE (very low), QQEE (low), QQQE (moderate), and QQQQ (high).
- The guideline was developed by a chair selected by The Endocrine Society Clinical Guidelines Subcommittee, five additional experts, and a methodologist; evidence included observational/epidemiological studies and a systematic review/meta-analysis commissioned by The Endocrine Society.
- Funding was derived solely from The Endocrine Society, and the Task Force received no corporate funding or remuneration.
Limitations
- The Task Force states that it acknowledges the observational nature of the available evidence and dependence on epidemiological studies, and that it made several strong recommendations based on assumptions about patients’ values and preferences.
- The paper states that whether serum triglycerides are causally related to atherosclerosis remains to be elucidated, that elevated triglycerides may sometimes be a marker rather than a causal factor, and that there is a lack of clear human data showing triglyceride reductions reduce cardiovascular disease.
- Stated limitations of specific evidence include lack of standardization and reference levels for nonfasting triglycerides, and for the Copenhagen City Heart Study analysis, a small number of subjects with high triglycerides, no adjustment for HDL cholesterol, and lack of fasting triglyceride levels for comparison.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
53 Valid · 24 Not valid · 106 Not checked · 100 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Epidemiological studies vary as to the independent association between large or small LDL and atherosclerotic cardiovascular disease (30).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.3. Evidence
What the sources say
- Partly supportedcites [30] Austin, 1990, Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk., Circulation sourceExperimental — accuracy not yet measured
The introduction (p. 495) reports that the small, dense LDL phenotype was associated with increased myocardial infarction risk, consistent with two previous studies. But the paper does not say that epidemiological studies vary in their findings about an independent association of large or small LDL with cardiovascular disease. Its multivariate analysis examines associations with LDL phenotype, not independent associations with disease. (LLM, conf=0.82)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Prospective multivariate studies demonstrate that large LDL predicts atherosclerosis and coronary heart disease (35,38,39).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.3. Evidence
What the sources say
- Not checked — no full text of the sourcecites [35] Sacks, 2003, Low density lipoprotein and cardiovascular disease: a reappraisal. (Clinical Review 163)., J Clin Endocrinol Metab source
- Partly supportedcites [38] Mora, 2009, Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women., Circulation sourceExperimental — accuracy not yet measured
The Results (Association of NMR Lipoproteins, Lipids, and Apolipoproteins with CVD; page unavailable) report that large LDL particles were significantly associated with incident cardiovascular disease in women when all nine particle subclasses were included in the model. They were not associated with cardiovascular disease in the separate adjusted model. The paper does not establish that large LDL specifically predicts atherosclerosis or coronary heart disease. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [39] Campos, 2001, Low density lipoprotein size, pravastatin treatment, and coronary events., JAMA source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Several reports also show that measurement of apoB is superior to measurement of LDL or even non-HDL cholesterol as an indicator of global CVD risk (40,41).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.3. Evidence
What the sources say
- Not checked — no full text of the sourcecites [40] de Graaf, 2008, A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias., Nat Clin Pract Endocrinol Metab source
- Supportedcites [41] Holewijn, 2010, Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk., J Intern Med source
The Discussion reports that, in this population-based sample, apoB identified people with a compromised cardiovascular risk profile more effectively than non-HDL cholesterol, while LDL cholesterol was least effective. It also reports significantly greater discrimination of prevalent CVD for apoB than for non-HDL cholesterol. The finding is based on this cohort; the authors note that a cited meta-analysis found no difference between apoB and non-HDL cholesterol. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several prospective studies suggest that circulating levels of small, dense LDL particles are better predictors of coronary atherosclerosis, carotid atherosclerosis, and response to therapy than are levels of large, buoyant LDL particles (28,(31)(32)(33).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.3. Evidence
What the sources say
- Partly supportedcites [28] Zambon, 1999, Evidence for a new pathophysiological mechanism for coronary artery regression: hepatic lipase-mediated changes in LDL density., Circulation sourceExperimental — accuracy not yet measured
The Abstract reports prospective associations between LDL size or density and coronary artery disease, and says patients with small, dense LDL responded better to therapy than those with large, buoyant LDL. The Results link changes in LDL buoyancy to changes in coronary stenosis. The cited paper does not address carotid atherosclerosis, so it does not support that part of the claim. Page numbers are unavailable in our copy. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [31] St-Pierre, 2005, Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study., Arterioscler Thromb Vasc Biol source
- Not checked — no full text of the sourcecites [32] Mora, 2007, LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA)., Atherosclerosis source
- Partly supportedcites [33] Musunuru, 2009, Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk., Arterioscler Thromb Vasc Biol sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports that small and medium LDL particle levels were associated with cardiovascular disease, whereas large LDL particle levels were not significantly related; it also says this pattern agrees with prospective cohorts including a study of carotid atherosclerosis. It does not establish that small, dense LDL levels predict response to therapy better than large LDL levels. Instead, the Discussion proposes evaluating lipoprotein measures in treatment studies as future work. (LLM, conf=0.84)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Prospective studies have indicated that, compared with fasting levels, nonfasting serum triglyceride levels may be a better or similar predictor of CVD events in the general population (15-18).”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.2. Evidence
What the sources say
- Not checked — no full text of the sourcecites [15] Nordestgaard, 2007, Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women., JAMA source
- Not checked — no full text of the sourcecites [16] Bansal, 2007, Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women., JAMA source
- Supportedcites [17] Mora, 2008, Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events., Circulation source
The paper’s introductory passage says three studies suggested that nonfasting triglycerides may predict CVD events better than or similarly to fasting levels. Its Results also report a stronger association for nonfasting triglycerides in its prospective cohort of initially healthy women. No page number is available in our copy. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [18] Stalenhoef, 2008, Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small, dense LDL., Curr Opin Lipidol source
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
149 more claims · 26 with their cited sources checked
Create a free account to see all 283 claims and every source verdict.
- Probably not a substantial claim. 53
- It may state two separate claims as one. 94
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HTG may result from impaired clearance of TRLs, most often due to pathogenic variants in the lipolytic pathway, ranging from monogenic defects in LPL gene or its cofactors (APOC2, APOA5, LMF1, and GPIHBP1) to polygenic susceptibility, and may be exacerbated by secondary factors such as diabetes, obesity, alcohol use, and certain medications [5, 6].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current management strategies for HTG and mixed dyslipidemia provide limited and inconsistent benefits in TG lowering and cardiovascular outcomes, underscoring the need for more effective and durable approaches targeting TRL and apoB-containing lipoproteins (Filtz et al., 2024; Berglund et al., 2012; Chapman et al., 2011).”
From Efficacy and safety of small interfering RNA (siRNA) therapies for hypertriglyceridemia and mixed dyslipidemia: an updated systematic review and meta-analysis (2026) · cites this paper as Berglund et al., 2012
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A delay in diagnosis may place patients at an increased risk for acute pancreatitis.11”
From Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span (2018) · cites this paper as [11]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The APPROACH trial showed that volanesorsenmediated lowering of plasma apolipoprotein C-III levels in patients with familial chylomicronemia syndrome effectively lowered plasma triglycerides below the threshold of 750 to 880 mg per deciliter”
From Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome (2019) · cites this paper as [22]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Acute pancreatitis can lead to chronic pancreatitis, 10,11 signs of exocrine or endocrine pancreatic insufficiency, including pancreatic (type 3c) diabetes, 12 and can be fatal.”
From Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span (2018) · cites this paper as [11]
Experimental — accuracy not yet measured
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.1. Evidence
“Of subjects with hypertriglyceridemia, about 14% had mild hypertriglyceridemia (150 -200 mg/dl), whereas 16% had triglyceride levels of 200 -500 mg/dl, and about 2% had levels above 500 mg/dl.”
§ Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline > 1.1. Evidence
“In the National Health and Nutrition Examination Survey (NHANES), 1999 -2004, 33% of the nearly 6000 participants (37% men, 30% women) had serum triglycerides of at least 150 mg/dl (Ն1.7 mmol/liter) (5).”
Citations
Cites
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860 · cited 7×
“Cosponsoring Associations: American Heart Association, European Society of Endocrinology.”
InfluentialDetection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation group (1).”
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Mensink, R. P., Zock, P. L., Kester, A. D., & Katan, M. B. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.5.1146 · Cited by 2,811 · cited 2×
“urated or polyunsaturated fat lowers LDL cholesterol; n-6 polyunsaturated fats have a stronger LDL-lowering effect than monounsaturated fats (152).”
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516 · cited 1×
“EPA added to statin therapy in subjects with cholesterol levels above 250 mg/dl in an open-label study resulted in a 19% relative reduction in major coronary events (180).”
(1999) · PubMed · Cited by 2,062
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058 · cited 3×
“women than those reported in the Copenhagen City Heart Study (15).”
InfluentialBrown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates
Sacks, F. M., Bray, G. A., Carey, V. J., Smith, S. R., Ryan, D. H., Anton, S. D., McManus, K., Champagne, C. M., Bishop, L. M., Laranjo, N., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0804748 · Cited by 1,966 · cited 1×
“bohydrate diets and low-carbohydrate diets (162, 163).”
Self-citationFifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
Ludwig (2002) · doi:10.1001/jama.287.18.2414 · Cited by 1,775 · cited 1×
“The glycemic index may correlate with the extent of rise of serum triglyceride after eating carbohydrate-rich foods (154).”
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Hokanson, J. E., & Austin, M. A. (1996) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199604000-00014 · Cited by 1,706 · cited 1×
“5 mg/dl) increase of triglycerides (132).”
Atherogenesis: a postprandial phenomenon.
Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619 · cited 2×
“The Women’s Health Study (16) followed 26,509 initially healthy U.S. women older than 45 yr of age for a median of 11.4 yr; testing was done in 20,118 fasting and 6,391 nonfasting participants.”
InfluentialSelf-citationAtherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
Austin, M. A., King, M. C., Vranizan, K. M., & Krauss, R. M. (1990) · Circulation · doi:10.1161/01.cir.82.2.495 · Cited by 1,411 · cited 1×
“Epidemiological studies vary as to the independent association between large or small LDL and atherosclerotic cardiovascular disease (30).”
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408 · cited 2×
“More recently, a report of two nested case-control comparisons from population-based cohorts [the Reykjavik study and the European Prospective Investigation of Cancer (EPIC)-Norfolk study] comprised 44,237 Western middle-age men and women of predominantly European ancestry and a total of 3,582 cases of coronary heart…”
Tabas, I., Williams, K. J., & Borén, J. (2007) · Circulation · doi:10.1161/circulationaha.106.676890 · Cited by 1,399
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Kamstrup, P. R. (2009) · JAMA · doi:10.1001/jama.2009.801 · Cited by 1,357
The mysteries of lipoprotein(a).
Utermann, G. (1989) · Science · doi:10.1126/science.2530631 · Cited by 1,257 · cited 1×
“Lp(a) has many properties in common with LDL but contains a unique protein, apolipoprotein(a), which is linked to apoB-100 by a single disulfide bond (42).”
Johnson, R. K., Appel, L. J., Brands, M., Howard, B. V., Lefevre, M., Lustig, R. H., Sacks, F., Steffen, L. M., & Wylie-Rosett, J. (2009) · Circulation · doi:10.1161/circulationaha.109.192627 · Cited by 1,207
Self-citationAppel, L. J., Sacks, F. M., Carey, V. J., Obarzanek, E., Swain, J. F., Miller, E. R., Conlin, P. R., Erlinger, T. P., Rosner, B. A., Laranjo, N. M., et al. (2005) · JAMA · doi:10.1001/jama.294.19.2455 · Cited by 1,170 · cited 4×
“Compared with a diet that emphasized carbohydrate, a similar diet that emphasized protein decreased triglyceride levels further, and this decrease was about twice the effect of a diet that emphasized unsaturated fat (155).”
InfluentialSelf-citationThe glycemic index: methodology and clinical implications
Wolever, T., Jenkins, D., Jenkins, A., & Josse, R. (1991) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/54.5.846 · Cited by 1,168 · cited 1×
“Thisdifference is expressedby the glycemic index, which is the rise in blood glucose of 50 g of carbohydrate in a specific food compared with either 50 g glucose or white bread (153).”
A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction.
Stampfer, M. J., Sacks, F. M., Salvini, S., Willett, W. C., & Hennekens, C. H. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108083250601 · Cited by 1,163
Self-citationWalsh, B. W., Schiff, I., Rosner, B., Greenberg, L., Ravnikar, V., & Sacks, F. M. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110243251702 · Cited by 1,152
Self-citationRelation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state
Patsch, J. R., Miesenböck, G., Hopferwieser, T., Mühlberger, V, Knapp, E., Dunn, J. K., Gotto, A. M., & Patsch, W. (1992) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.12.11.1336 · Cited by 1,122 · cited 1×
“In a number of studies using standardized meals on the association of postprandial lipemia with CVD, greater CVD risk was found to be associated with increased hypertriglyceridemia (19, 20).”
Lamarche, B., Tchernof, A., Moorjani, S., Cantin, B., Dagenais, G. R., Lupien, P. J., & Despre´s, J.-P. (1997) · Circulation · doi:10.1161/01.cir.95.1.69 · Cited by 1,077
Carr, A., Samaras, K., Chisholm, D. J., & Cooper, D. A. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03391-1 · Cited by 1,065 · cited 1×
“Other conditions Acquired lipodystrophy can be seen in patients with HIV infection who are being treated with highly active antiretroviral therapy (99).”
Fish and Omega-3 Fatty Acid Intake and Risk of Coronary Heart Disease in Women
Hu, F. B. (2002) · JAMA · doi:10.1001/jama.287.14.1815 · Cited by 1,018
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60656-3 · Cited by 927
Fish consumption and the 30-year risk of fatal myocardial infarction
Daviglus, M. L., Stamler, J., Orencia, A. J., Dyer, A. R., Liu, K., Greenland, P., Walsh, M. K., Morris, D., & Shekelle, R. B. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704103361502 · Cited by 902
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
Graham, D. J. (2004) · JAMA · doi:10.1001/jama.292.21.2585 · Cited by 875 · cited 1×
“Muscle symptoms ranging from leg cramps to aching to weakness occur in about 10% of patients, whereas rhabdomyolysis is rare (185).”
ISCHÆMIC HEART-DISEASE IN RELATION TO FASTING VALUES OF PLASMA TRIGLYCERIDES AND CHOLESTEROL
Carlson, L., & Böttiger, L. E. (1972) · The Lancet · doi:10.1016/s0140-6736(72)90738-6 · Cited by 752
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
De Clercq, E. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.10.010 · Cited by 627 · cited 1×
“In particular, the protease inhibitors ritonavir and lopinavir can increase plasma triglyceride levels (114).”
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L. (2011) · Diabetes Care · doi:10.2337/dc10-1068 · Cited by 625
Havel, P. J. (2005) · Nutrition Reviews · doi:10.1111/j.1753-4887.2005.tb00132.x · Cited by 607 · cited 1×
“Foods that contain potent substrates for triglyceride production such as simple sugars, fructose, and alcohol can substantially increase triglyceride levels in susceptible people (80, 81).”
Familial lipoprotein disorders in patients with premature coronary artery disease.
Genest, J. J., Martin-Munley, S. S., McNamara, J. R., Ordovas, J. M., Jenner, J., Myers, R. H., Silberman, S. R., Wilson, P. W., Salem, D. N., & Schaefer, E. J. (1992) · Circulation · doi:10.1161/01.cir.85.6.2025 · Cited by 596 · cited 1×
“(119, 120) proposed that familial hypoalphalipoproteinemia (FHA), a disorder with elevated triglyceride and low HDL cholesterol, was a common genetic dyslipidemia associated with premature CVD.”
Lipoprotein Management in Patients With Cardiometabolic Risk
Brunzell, J. D., Davidson, M., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., & Witztum, J. L. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.02.034 · Cited by 529
Self-citationHeiss, G., Tamir, I., Davis, C. E., Tyroler, H. A., Rifkand, B. M., Schonfeld, G., Jacobs, D., & Frantz, I. D. (1980) · Circulation · doi:10.1161/01.cir.61.2.302 · Cited by 526
Foster, G. D., Wyatt, H. R., Hill, J. O., Makris, A. P., Rosenbaum, D. L., Brill, C., Stein, R. I., Mohammed, B. S., Miller, B., Rader, D. J., et al. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-3-201008030-00005 · Cited by 520 · cited 1×
“bohydrate diets and low-carbohydrate diets (162, 163).”
Lipid accumulation in non-adipose tissue and lipotoxicity
van Herpen, N. A., & Schrauwen-Hinderling, V. B. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.11.049 · Cited by 500 · cited 1×
“Cellular and animal experiments suggest that signaling lipids other than triglyceride, such as ceramides or diacylglycerols, maybepathological (131).”
Carr, M. C., & Brunzell, J. D. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0432 · Cited by 493 · cited 2×
“Type 2 diabetes mellitus, polycystic ovary syndrome, and FCHL may account for at least 40–50% of premature coronary artery disease in some populations with metabolic syndrome, and they need to be considered in assessing the risk of CVD in patients who have the metabolic syndrome (26).”
Self-citationMora, S., Otvos, J. D., Rifai, N., Rosenson, R. S., Buring, J. E., & Ridker, P. M. (2009) · Circulation · doi:10.1161/circulationaha.108.816181 · Cited by 490 · cited 1×
“Prospective multivariate studies demonstrate that large LDL predicts atherosclerosis and coronary heart disease (35, 38, 39).”
Brunzell, J. D., Hazzard, W. R., Porte, D., & Bierman, E. L. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107334 · Cited by 484 · cited 2×
“Clearance of VLDL from the circulation is reduced in many patients with hypertriglyceridemia (64, 65, 73), in part due to saturation of triglyceride clearance (74).”
Self-citationMahley, R. W., Huang, Y., & Rall, S. C. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32417-2 · Cited by 447
Mora, S., Rifai, N., Buring, J. E., & Ridker, P. M. (2008) · Circulation · doi:10.1161/circulationaha.108.777334 · Cited by 445
St-Pierre, A. C., Cantin, B., Dagenais, G. R., Mauriège, P., Bernard, P.-M., Després, J.-P., & Lamarche, B. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000154144.73236.f4 · Cited by 422
Mora, S., Szklo, M., Otvos, J. D., Greenland, P., Psaty, B. M., Goff, D. C., O’Leary, D. H., Saad, M. F., Tsai, M. Y., & Sharrett, A. R. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.05.007 · Cited by 380
van der Steeg, W. A., Holme, I., Boekholdt, S. M., Larsen, M. L., Lindahl, C., Stroes, E. S. G., Tikkanen, M. J., Wareham, N. J., Faergeman, O., Olsson, A. G., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.060 · Cited by 374
Postprandial lipoprotein metabolism and atherosclerosis.
Karpe, F. (1999) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1999.00548.x · Cited by 360 · cited 1×
“In a number of studies using standardized meals on the association of postprandial lipemia with CVD, greater CVD risk was found to be associated with increased hypertriglyceridemia (19, 20).”
Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region.
Asia Pacific Cohort Studies Collaboration (2004) · Circulation · doi:10.1161/01.cir.0000145615.33955.83 · Cited by 358
Summary of American Heart Association Diet and Lifestyle Recommendations Revision 2006
Lichtenstein, A. H., Appel, L. J., Brands, M., Carnethon, M., Daniels, S., Franch, H. A., Franklin, B., Kris-Etherton, P., Harris, W. S., Howard, B., et al. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000238352.25222.5e · Cited by 345 · cited 1×
“Foods that contain potent substrates for triglyceride production such as simple sugars, fructose, and alcohol can substantially increase triglyceride levels in susceptible people (80, 81).”
Self-citationMechanism of plasma cholesteryl ester transfer in hypertriglyceridemia.
Mann, C. J., Yen, F. T., Grant, A. M., & Bihain, B. E. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115535 · Cited by 339
Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM.
Malmström, R., Packard, C. J., Caslake, M., Bedford, D., Stewart, P., Yki-Järvinen, H., Shepherd, J., & Taskinen, M.-R. (1997) · Diabetologia · doi:10.1007/s001250050700 · Cited by 319 · cited 1×
“Hepatic insulin resistance may contribute to a high production rate of VLDL because insulin reduces apoB synthesis and VLDL secretion in the liver (66, 67).”
Hepatic lipid metabolism and non-alcoholic fatty liver disease
Tessari, P., Coracina, A., Cosma, A., & Tiengo, A. (2009) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.12.015 · Cited by 314
Cheal, K. L., Abbasi, F., Lamendola, C., McLaughlin, T., Reaven, G. M., & Ford, E. S. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1195 · Cited by 312 · cited 1×
“Although insulin resistance is associated with high triglycerides, VLDL and triglyceride concentrations can be similar in patients with widely divergent insulin sensitivity (68, 69).”
Safety and Efficacy of Omacor in Severe Hypertriglyceridemia
Harris, W. S., Ginsberg, H. N., Arunakul, N., Shachter, N. S., Windsor, S. L., Adams, M., Berglund, L., & Osmundsen, K. (1997) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182679700400511 · Cited by 306
Self-citationSwiglo, B. A., Murad, M. H., Schünemann, H. J., Kunz, R., Vigersky, R. A., Guyatt, G. H., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1907 · Cited by 302 · cited 1×
“this grading scheme has been published (2).”
Self-citationAsztalos, B. F., Cupples, L. A., Demissie, S., Horvath, K. V., Cox, C. E., Batista, M. C., & Schaefer, E. J. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000146325.93749.a8 · Cited by 298
Circulating interferon-α levels and hypertriglyceridemia in the acquired immunodeficiency syndrome
Grunfeld, C., Kotler, D. P., Shigenaga, J. K., Doerrler, W., Tierney, A., Wang, J., Pierson, R. N., & Feingold, K. R. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)80154-e · Cited by 286
Circulating interferon-α levels and hypertriglyceridemia in the acquired immunodeficiency syndrome.
Grunfeld, C., Kotler, D. P., Shigenaga, J. K., Doerrler, W., Tierney, A., Wang, J., Pierson, R. N., & Feingold, K. R. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90536-7 · Cited by 286
Apolipoprotein C-III: understanding an emerging cardiovascular risk factor
Ooi, E. M. M., Barrett, P. H. R., Chan, D. C., & Watts, G. F. (2008) · Clinical Science · doi:10.1042/cs20070308 · Cited by 282 · cited 2×
“Clearance of VLDL from the circulation is reduced in many patients with hypertriglyceridemia (64, 65, 73), in part due to saturation of triglyceride clearance (74).”
Nieves, D. J., Cnop, M., Retzlaff, B., Walden, C. E., Brunzell, J. D., Knopp, R. H., & Kahn, S. E. (2003) · Diabetes · doi:10.2337/diabetes.52.1.172 · Cited by 281 · cited 2×
“Increased visceral fat is associated with insulin resistance, hyperinsulinemia, low plasma adiponectin levels, and elevations in plasma NEFA levels (127).”
Self-citationBennet, A. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.6.598 · Cited by 281
Brunzell, J. D. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp070061 · Cited by 268 · cited 6×
“These patients are at risk for acute, recurrent pancreatitis with severe hypertriglyceridemia, and they must be treated with moderate to severe dietary fat restriction to reduce plasma triglyceride levels (78).”
InfluentialSelf-citationAssociation of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis.
SNIDERMAN, A. D., WOLFSON, C., TENG, B., FRANKLIN, F. A., BACHORIK, P. S., & KWITEROVICH, P. O. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-6-833 · Cited by 266 · cited 1×
“It is not necessary to measure LDL size or density; however, measurement of non-HDL cholesterol and/or apoB levels can indicate the presence of increased numbers of LDL particles (3, 29).”
Brinton, E. A., Eisenberg, S., & Breslow, J. L. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.5.707 · Cited by 265 · cited 5×
“Small HDL in hypertriglyceridemia is associated with hypercatabolism of apolipoprotein A-I (47, 48), and it seems to be related to elevated hepatic lipase activity in central obesity and insulin resistance (49).”
InfluentialZambon, A., Hokanson, J. E., Brown, B. G., & Brunzell, J. D. (1999) · Circulation · doi:10.1161/01.cir.99.15.1959 · Cited by 263 · cited 1×
“Hepatic lipase and cholesterol ester transfer protein contribute to the remodeling processes; whether hepatic lipase or cholesterol ester transfer protein has the predominant effect on the size and density of LDL and HDL particles depends on the triglyceride content of very low-density lipoproteins (VLDL) (27, 28).”
Self-citationThe biochemical, clinical, and genetic features of type III hyperlipoproteinemia.
MORGANROTH, J., LEVY, R. I., & FREDRICKSON, D. S. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-82-2-158 · Cited by 260
Austin, M. A., McKnight, B., Edwards, K. L., Bradley, C. M., McNeely, M. J., Psaty, B. M., Brunzell, J. D., & Motulsky, A. G. (2000) · Circulation · doi:10.1161/01.cir.101.24.2777 · Cited by 255 · cited 1×
“FHTG does not appear to be associated with an increased risk of premature CVD (118).”
Self-citationNew Perspectives on Atherogenesis: Role of Abnormal Triglyceride-Rich Lipoprotein Metabolism
Ginsberg, H. N. (2002) · Circulation · doi:10.1161/01.cir.0000035280.64322.31 · Cited by 255 · cited 3×
“Evidence In most hypertriglyceridemic patients, the distribution of both LDL and HDL sizes is shifted to smaller particles (24).”
Safety and efficacy of Omacor in severe hypertriglyceridemia
Harris, W. S., Ginsberg, H. N., Arunakul, N., Shachter, N. S., Windsor, S. L., Adams, M., Berglund, L., & Osmundsen, K. (1997) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199710000-00011 · Cited by 252
Self-citationGrundy, S. M. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000189155.75833.c7 · Cited by 247
Low-Density Lipoprotein Size and Cardiovascular Disease: A Reappraisal
Sacks, F. M., & Campos, H. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030636 · Cited by 241
Self-citationPrevalence of abnormal lipid levels among youths --- United States, 1999-2006.
May, A. L., Kuklina, E. V., & Yoon, P. W. (2010) · MMWR Morbidity and Mortality Weekly Report · Cited by 239
Sumner, A. E., Finley, K. B., Genovese, D. J., Criqui, M. H., & Boston, R. C. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1395 · Cited by 230 · cited 1×
“In African-Americans, low triglyceride levels occur in the context of severe insulin resistance (72).”
(2001) · Medical Entomology and Zoology · Cited by 227
Self-citationEberly, L. E. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1077 · Cited by 226
Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia.
Péterfy, M., Ben-Zeev, O., Mao, H. Z., Weissglas-Volkov, D., Aouizerat, B. E., Pullinger, C. R., Frost, P. H., Kane, J. P., Malloy, M. J., Reue, K., et al. (2007) · Nature Genetics · doi:10.1038/ng.2007.24 · Cited by 226 · cited 1×
“Defective lipolysis occurs with genetic defects in LpL; defects in apoC-II; defective association of LpL with the vascular wall due to antibodies to heparin or defects in glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1, an LpL-binding protein (75, 76); or defective intracellular LpL pr…”
Vascular endothelium: an integrator of pathophysiologic stimuli in atherosclerosis.
Gimbrone, M. A. (1995) · The American Journal of Cardiology · doi:10.1016/0002-9149(95)80016-l · Cited by 225 · cited 1×
“(148), and promotion of coagulation (149).”
Tambalis, K., Panagiotakos, D. B., Kavouras, S. A., & Sidossis, L. S. (2009) · Angiology · doi:10.1177/0003319708324927 · Cited by 224
Zheng, C., Khoo, C., Furtado, J., & Sacks, F. M. (2010) · Circulation · doi:10.1161/circulationaha.109.875807 · Cited by 223
Self-citationChanges in plasma lipids and lipoproteins during isotretinoin therapy for acne.
Bershad, S., Rubinstein, A., Paterniti, J. R., Le, N.-A., Poliak, S. C., Heller, B., Ginsberg, H. N., Fleischmajer, R., & Brown, W. V. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510173131604 · Cited by 217
Lipodystrophy: metabolic insights from a rare disorder
Huang-Doran, I., Sleigh, A., Rochford, J. J., O'Rahilly, S., & Savage, D. B. (2010) · Journal of Endocrinology · doi:10.1677/joe-10-0272 · Cited by 215
Hypertriglyceridemia and its pharmacologic treatment among US adults.
Ford, E. S., Li, C., Zhao, G., Pearson, W. S., & Mokdad, A. H. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.599 · Cited by 214 · cited 1×
“higher in men and increase with age in both sexes (5).”
Aarsland, A., Chinkes, D., & Wolfe, R. R. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119005 · Cited by 212 · cited 1×
“Acute or chronic elevation of insulin in response to a high carbohydrate diet did not lower serum triglyceride levels in healthy subjects (70, 71).”
Postprandial hyperlipidemia and remnant lipoproteins.
Havel, R. J. (1994) · Current Opinion in Lipidology · doi:10.1097/00041433-199404000-00006 · Cited by 209
Maio, A., & Dowd, F. J. (2010) · xPharm: The Comprehensive Pharmacology Reference · doi:10.1016/b978-008055232-3.60628-2 · Cited by 209
Ectopic lipids and organ function.
Szendroedi, J., & Roden, M. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328321b3a8 · Cited by 200 · cited 1×
“Hepatic steatosis is often associated with increased intraabdominal fat and fat accumulation in other tissues such as skeletal muscle, heart, and perhaps pancreas, and may lead to insulin resistance associated with type 2 diabetes and metabolic syndrome (130).”
Secondary causes of hyperlipidemia.
Stone, N. J. (1994) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30179-1 · Cited by 199 · cited 2×
“These effects are most relevant in patients with underlying genetic hypertriglyceridemia (94).”
Cohn, J. S., McNamara, J. R., Cohn, S. D., Ordovas, J. M., & Schaefer, E. J. (1988) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38485-6 · Cited by 195
Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender and diet.
Deeb, S. S., Zambon, A., Carr, M. C., Ayyobi, A. F., & Brunzell, J. D. (2003) · Journal of Lipid Research · doi:10.1194/jlr.r200017-jlr200 · Cited by 193 · cited 1×
“Small HDL in hypertriglyceridemia is associated with hypercatabolism of apolipoprotein A-I (47, 48), and it seems to be related to elevated hepatic lipase activity in central obesity and insulin resistance (49).”
Self-citationThe Emerging Risk Factors Collaboration (2007) · European Journal of Epidemiology · doi:10.1007/s10654-007-9165-7 · Cited by 188 · cited 1×
“2 million participants in a central database with individual data records (136).”
Lipodystrophies: disorders of adipose tissue biology.
Garg, A., & Agarwal, A. K. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2008.12.014 · Cited by 184 · cited 1×
“Rare genetic disorders Inherited and congenital lipodystrophies are associated with moderate-to-severe hypertriglyceridemia and are characterized by loss of adipose tissue and either autosomal recessive or dominant inheritance (95).”
Lipid-lowering agents that cause drug-induced hepatotoxicity.
Bhardwaj, S. S., & Chalasani, N. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.06.010 · Cited by 173 · cited 1×
“The most serious complication of niacin therapy is hepatotoxicity (which is dose dependent), and therapy should be accompanied by monitoring of liver function tests (178).”
Cohn, J. S., Patterson, B. W., Uffelman, K. D., Davignon, J., & Steiner, G. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032056 · Cited by 170 · cited 2×
“The increase in triglyceride production may be due to excess free fatty acids returning to the liver, particularly in the setting of visceral obesity and insulin resistance, and increased de novo triglyceride production due to hyperinsulinemia (24, 62, 63).”
Musunuru, K., Orho-Melander, M., Caulfield, M. P., Li, S., Salameh, W. A., Reitz, R. E., Berglund, G., Hedblad, B., Engström, G., Williams, P. T., et al. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.190405 · Cited by 168
FREQUENCY OF RISK FACTORS FOR ISCHÆMIC HEART-DISEASE IN A HEALTHY BRITISH POPULATION
Lewis, B., Wootton, I. D. P., Krikler, D. M., February, A., Chait, A., Oakley, C. M., Sigurdsson, G., Maurer, B., & Birkhead, J. (1974) · The Lancet · doi:10.1016/s0140-6736(74)92438-6 · Cited by 165
Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes.
Ip, S., Lichtenstein, A. H., Chung, M., Lau, J., & Balk, E. M. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-7-200904070-00007 · Cited by 163
How safe is the use of thiazolidinediones in clinical practice?
Rizos, C., Elisaf, M., Mikhailidis, D., & Liberopoulos, E. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330802597821 · Cited by 161
Nordestgaard, B. G., Tybjaerg-Hansen, A., & Lewis, B. (1992) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.12.1.6 · Cited by 159 · cited 1×
“Very large triglyceride-rich lipoproteins, perhaps equivalent to unmetabolized chylomicrons, are not atherogenic if they are too large to penetrate into the arterial wall (60, 137).”
Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus.
Brunzell, J. D., & Ayyobi, A. F. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.08.011 · Cited by 155 · cited 1×
“the presence of central obesity and insulin resistance (83).”
Self-citationChanges in triglyceride levels and risk for coronary heart disease in young men.
Tirosh, A., Rudich, A., Shochat, T., Tekes-Manova, D., Israeli, E., Henkin, Y., Kochba, I., & Shai, I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-6-200709180-00007 · Cited by 151 · cited 4×
“Beyond fasting triglyceride levels, the change in triglyceride levels strongly predicted incident coronary heart disease (135).”
InfluentialTriglycerides as vascular risk factors: new epidemiologic insights.
Kannel, W. B., & Vasan, R. S. (2009) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32832c1284 · Cited by 149 · cited 1×
“Although triglyceride itself is not a component of arterial plaque, it is thought that cholesterol within triglyceride-rich particles may contribute to plaque development (60, 61).”
The Metabolic Basis of Inherited Disease
Clark, J. H. (1991) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/j.1536-4801.1991.tb10474.x · Cited by 144
Brown, B. G., Zhao-Q, X., Chait, A., & Fisher, L. D. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00657-8 · Cited by 144
Vu-Dac, N., Gervois, P., Torra, I. P., Fruchart, J. C., Kosykh, V, Kooistra, T., Princen, H. M., Dallongeville, J., & Staels, B. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1581 · Cited by 143
Karpe, F., Bell, M., Björkegren, J., & Hamsten, A. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.2.199 · Cited by 143
Effect of Fibrates on Lipid Profiles and Cardiovascular Outcomes: A Systematic Review
Abourbih, S., Filion, K. B., Joseph, L., Schiffrin, E. L., Rinfret, S., Poirier, P., Pilote, L., Genest, J., & Eisenberg, M. J. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.030 · Cited by 139
Veerkamp, M. J., Graaf, J. D., Hendriks, J. C. M., Demacker, P. N. M., & Stalenhoef, A. F. H. (2004) · Circulation · doi:10.1161/01.cir.0000130646.93255.86 · Cited by 139 · cited 1×
“It has been suggested that measurement of apoB and non-HDL cholesterol levels, in addition to assessment of LDL and HDL cholesterol levels, will serve as a basis by which to identify these FCHL individuals at risk for premature CVD (117).”
Self-citationLow density lipoprotein size, pravastatin treatment, and coronary events.
Campos, H. (2001) · JAMA · doi:10.1001/jama.286.12.1468 · Cited by 132 · cited 2×
“Prospective multivariate studies demonstrate that large LDL predicts atherosclerosis and coronary heart disease (35, 38, 39).”
Hypertriglyceridemia: a contraindication to the use of bile acid binding resins.
Crouse, J. R. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90692-9 · Cited by 130 · cited 1×
“Patients with normal baseline triglyceride levels experience minimal triglyceride increases with bile acid sequestrant therapy, but those with moderate hypertriglyceridemia (triglycerides 200 mg/dl) may experience substantial further elevation (113).”
FoxO1 integrates insulin signaling to VLDL production.
Kamagate, A., & Dong, H. H. (2008) · Cell Cycle · doi:10.4161/cc.7.20.6882 · Cited by 127 · cited 1×
“Hepatic insulin resistance may contribute to a high production rate of VLDL because insulin reduces apoB synthesis and VLDL secretion in the liver (66, 67).”
Alcohol-induced changes in serum lipoproteins and in their metabolism.
Taskinen, M.-R., Nikkilä, E. A., Välimäki, M., Sane, T., Kuusi, T., Kesäniemi, Y. A., & Ylikahri, R. (1987) · American Heart Journal · doi:10.1016/0002-8703(87)90614-4 · Cited by 122 · cited 1×
“The effects of alcohol vary interindividually, tend to be amplified in subjects with underlying lipid disorders, are dose-dependent (106), and may be related to the mode of intake (107).”
Stalenhoef, A. F., & de Graaf, J. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328304b63c · Cited by 121
Self-citationFamilial hypoalphalipoproteinemia in premature coronary artery disease.
Genest, J. J., Bard, J., Fruchart, J., Ordovás, J. M., & Schaefer, E. J. (1993) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.13.12.1728 · Cited by 119 · cited 1×
“(119, 120) proposed that familial hypoalphalipoproteinemia (FHA), a disorder with elevated triglyceride and low HDL cholesterol, was a common genetic dyslipidemia associated with premature CVD.”
Köbberling Type of Familial Partial Lipodystrophy
Herbst, K. L., Tannock, L. R., Deeb, S. S., Purnell, J. Q., Brunzell, J. D., & Chait, A. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1819 · Cited by 119
Self-citationChanges in Triglyceride Levels and Risk for Coronary Heart Disease in Young Men
(2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-6-200709180-00003 · Cited by 118
Mutation of conserved cysteines in the Ly6 domain of GPIHBP1 in familial chylomicronemia.
Olivecrona, G., Ehrenborg, E., Semb, H., Makoveichuk, E., Lindberg, A., Hayden, M. R., Gin, P., Davies, B. S. J., Weinstein, M. M., Fong, L. G., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m002717 · Cited by 118 · cited 1×
“Defective lipolysis occurs with genetic defects in LpL; defects in apoC-II; defective association of LpL with the vascular wall due to antibodies to heparin or defects in glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1, an LpL-binding protein (75, 76); or defective intracellular LpL pr…”
Prevalence of abnormal lipid levels among youths --- United States, 1999-2006.
(2010) · PubMed · Cited by 115
Ridker, P. M. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.097907 · Cited by 114 · cited 1×
“Although these studies provide some support for the hypothesis that nonfasting or postprandial lipid levels may be a more potent predictor of CVD risk than fasting levels, the lack of standardization and reference levels impedes a general implementation of nonfasting triglyceride or remnant particle levels (22).”
Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects.
Batal, R., Tremblay, M., Barrett, P. H. R., Jacques, H., Fredenrich, A., Mamer, O., Davignon, J., & Cohn, J. S. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32379-8 · Cited by 113
Effects of VLDL and remnant particles on platelets.
Olufadi, R., & Byrne, C. D. (2006) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000093221 · Cited by 111 · cited 1×
“(148), and promotion of coagulation (149).”
(2004) · PubMed · Cited by 108
Mechanism of hypertriglyceridaemia associated with contraceptive steroids.
Kissebah, A., Harrigan, P., & Wynn, V. (1973) · Hormone and Metabolic Research · doi:10.1055/s-0028-1093969 · Cited by 106 · cited 1×
“Oral estrogens increase the hepatic secretion of VLDL, leading in turn to an increase in serum triglyceride levels (108).”
Ayyobi, A. F., McGladdery, S. H., McNeely, M. J., Austin, M. A., Motulsky, A. G., & Brunzell, J. D. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000077220.44620.9b · Cited by 103 · cited 2×
“In patients with FCHL, increases in triglycerides and LDL cholesterol are often found, whereas elevated apoB levels and small, dense LDL particles are always seen (25).”
Self-citationLipid and lipoprotein metabolism in chronic kidney disease.
Kaysen, G. A. (2009) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2008.10.011 · Cited by 102
Rutledge, J. C., Woo, M. M., Rezai, A. A., Curtiss, L. K., & Goldberg, I. J. (1997) · Circulation Research · doi:10.1161/01.res.80.6.819 · Cited by 101 · cited 1×
“permeability of blood vessels (150), which may allow”
Self-citationVéniant, M. M., Pierotti, V, Newland, D., Cham, C. M., Sanan, D. A., Walzem, R. L., & Young, S. G. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119511 · Cited by 100 · cited 3×
“apoB-48 lipoproteins are clearly atherogenic as shown in a mouse model constructed with apoB-48 as the only type of apoB in VLDL and LDL (146).”
Influentialde Knijff, P., van den Maagdenberg, A. M., Stalenhoef, A. F., Leuven, J. A., Demacker, P. N., Kuyt, L. P., Frants, R. R., & Havekes, L. M. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115349 · Cited by 100 · cited 1×
“Other rare apoE variants such as apoE3-Leiden and apoE2(Lys1463Gln) can also cause dysbetalipoproteinemia (122, 123).”
Self-citationZhang, X., Qi, R., Xian, X., Yang, F., Blackstein, M., Deng, X., Fan, J., Ross, C., Karasinska, J., Hayden, M. R., et al. (2008) · Circulation Research · doi:10.1161/circresaha.107.156554 · Cited by 98 · cited 1×
“Although there are a number of severely hypertriglyceridemic animals, especially genetically modified mice, these animals develop only early-stage lesions (138, 139).”
Sweetnam, P. M., Bolton, C. H., Yarnell, J. W., Bainton, D., Baker, I. A., Elwood, P. C., & Miller, N. E. (1994) · Circulation · doi:10.1161/01.cir.90.2.769 · Cited by 98
Effects of ethanol intake on lipoproteins and atherosclerosis.
Brinton, E. A. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833c1f41 · Cited by 95 · cited 1×
“The effects of alcohol vary interindividually, tend to be amplified in subjects with underlying lipid disorders, are dose-dependent (106), and may be related to the mode of intake (107).”
Chunyu, Z., Christina, K., Katsunori, I., & Sacks, F. M. (2007) · Journal of Lipid Research · doi:10.1194/jlr.p600011-jlr200 · Cited by 95 · cited 2×
“Clearance of VLDL from the circulation is reduced in many patients with hypertriglyceridemia (64, 65, 73), in part due to saturation of triglyceride clearance (74).”
Self-citationEffects of pioglitazone on lipid and lipoprotein metabolism.
Betteridge, D. J. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00715.x · Cited by 91
Nakamura, T., Takano, H., Umetani, K., Kawabata, K.-I., Obata, J.-E., Kitta, Y., Kodama, Y., Mende, A., Ichigi, Y., Fujioka, D., et al. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.01.012 · Cited by 90
Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use
Mora, S. (2009) · Circulation · doi:10.1161/circulationaha.108.819359 · Cited by 89
Metabolic Effects of Rexinoids: Tissue-Specific Regulation of Lipoprotein Lipase Activity
Davies, P. J. A., Berry, S. A., Shipley, G. L., Eckel, R. H., Hennuyer, N., Crombie, D. L., Ogilvie, K. M., Peinado-Onsurbe, J., Fievet, C., Leibowitz, M. D., et al. (2001) · Molecular Pharmacology · doi:10.1124/mol.59.2.170 · Cited by 89
Murad, M. H., Hazem, A., Coto-Yglesias, F., Dzyubak, S., Gupta, S., Bancos, I., Lane, M. A., Erwin, P. J., Berglund, L., Elraiyah, T., et al. (2012) · BMC Endocrine Disorders · doi:10.1186/1472-6823-12-2 · Cited by 87 · cited 1×
“of cardiovascular events and pancreatitis (14).”
Self-citationDyslipidemia and nephrotic syndrome: recent advances.
Kronenberg, F. (2005) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2004.10.003 · Cited by 85 · cited 1×
“Nephrotic syndrome causes increased production of apoB-containing lipoproteins, including VLDL, by the liver (103).”
The acidic domain of GPIHBP1 is important for the binding of lipoprotein lipase and chylomicrons.
Gin, P., Yin, L., Davies, B. S. J., Weinstein, M. M., Ryan, R. O., Bensadoun, A., Fong, L. G., Young, S. G., & Beigneux, A. P. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802579200 · Cited by 85 · cited 1×
“Defective lipolysis occurs with genetic defects in LpL; defects in apoC-II; defective association of LpL with the vascular wall due to antibodies to heparin or defects in glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1, an LpL-binding protein (75, 76); or defective intracellular LpL pr…”
Disturbed lipid metabolism in glycogen storage disease type 1
Bandsma, R., Smit, P., & Kuipers, F. (2002) · European Journal of Pediatrics · doi:10.1007/s00431-002-1007-8 · Cited by 81
A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias.
de Graaf, J., Couture, P., & Sniderman, A. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0982 · Cited by 80
Sharma, M., Ansari, M. T., Abou-Setta, A. M., Soares-Weiser, K., Ooi, T. C., Sears, M., Yazdi, F., Tsertsvadze, A., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-9-200911030-00144 · Cited by 79 · cited 1×
“nations based on complementary mechanisms (169, 186).”
Smit, M., de Knijff, P., van der Kooij-Meijs, E., Groenendijk, C., van den Maagdenberg, A., Gevers Leuven, J., Stalenhoef, A., Stuyt, P., Frants, R., & Havekes, L. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42759-2 · Cited by 74
Self-citationMusa-Veloso, K., Binns, M. A., Kocenas, A. C., Poon, T., Elliot, J. A., Rice, H., Oppedal-Olsen, H., Lloyd, H., & Lemke, S. (2010) · Nutrition Reviews · doi:10.1111/j.1753-4887.2010.00272.x · Cited by 73 · cited 1×
“Approximately 3 to 4 g/d of EPA plus DHA are necessary to reduce hypertriglyceridemia by 20–50% (179).”
de Souza, R. J., Swain, J. F., Appel, L. J., & Sacks, F. M. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/88.1.1 · Cited by 72 · cited 3×
“Of subjects with hypertriglyceridemia, about 14% had mild hypertriglyceridemia (150–200 mg/dl), whereas 16% had triglyceride levels of 200–500 mg/dl, and about 2% had levels above 500 mg/dl. Recent surveys of youth and adolescents in the United States (NHANES cycle 1996–2006) and Germany revealed abnormal lipid levels…”
Self-citationThe interaction of familial and secondary causes of hypertriglyceridemia: role in pancreatitis
Brunzell, J. D., & Schrott, H. G. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.06.005 · Cited by 71
Self-citationChylomicronemia elicits atherosclerosis in mice—brief report.
Weinstein, M. M., Yin, L., Tu, Y., Wang, X., Wu, X., Castellani, L. W., Walzem, R. L., Lusis, A. J., Fong, L. G., Beigneux, A. P., et al. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.196329 · Cited by 71
Asztalos, B. F., Collins, D., Horvath, K. V., Bloomfield, H. E., Robins, S. J., & Schaefer, E. J. (2008) · Metabolism · doi:10.1016/j.metabol.2007.08.009 · Cited by 71
Chan, D. C., Watts, G. F., Nguyen, M. N., & Barrett, P. H. R. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000203519.25116.54 · Cited by 70 · cited 1×
“Clearance of VLDL from the circulation is reduced in many patients with hypertriglyceridemia (64, 65, 73), in part due to saturation of triglyceride clearance (74).”
Zhang, W.-Y., Schwartz, E., Wang, Y., Attrep, J., Li, Z., & Reaven, P. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000200226.53994.09 · Cited by 70 · cited 1×
“flammation (147), expression of adhesion molecules”
Stalenhoef, A. F., Malloy, M. J., Kane, J. P., & Havel, R. J. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112632 · Cited by 70 · cited 1×
“Patients with dysbetalipoproteinemia have elevations in both cholesterol and triglyceride levels (124).”
Self-citationSevere hypertriglyceridemia: role of familial and acquired disorders.
Chait, A., & Brunzell, J. D. (1983) · Metabolism · doi:10.1016/0026-0495(83)90184-1 · Cited by 69
Self-citationBlackburn, P., Lemieux, I., Alméras, N., Bergeron, J., Côté, M., Tremblay, A., Lamarche, B., & Després, J.-P. (2009) · Metabolism · doi:10.1016/j.metabol.2009.03.012 · Cited by 67 · cited 1×
“Increased waist circumference and plasma triglyceride levels together confer greater CVD risk in these patients (128).”
Inherited lipodystrophies and hypertriglyceridemia.
Simha, V., & Garg, A. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32832d4a33 · Cited by 67
Gylling, H., Vega, G., & Grundy, S. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41407-5 · Cited by 67
Holewijn, S., Den Heijer, M., Swinkels, D. W., H Stalenhoef, A. F., & De Graaf, J. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02277.x · Cited by 64 · cited 1×
“Several reports also show that measurement of apoB is superior to measurement of LDL or even non-HDL cholesterol as an indicator of global CVD risk (40, 41).”
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J., James, W. P., Loria, C. M., & Smith, S. C. J. (2010) · Obesity and metabolism · doi:10.14341/2071-8713-5281 · Cited by 62
BROWN, B. G., HILLGER, L., ZHAO, X., POULIN, D., & ALBERS, J. J. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb17337.x · Cited by 61
Campos, H., Khoo, C., & Sacks, F. M. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.12.045 · Cited by 58
Self-citationSuccessful hyperlipemic pregnancy.
Sanderson, S. L. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03460140086032 · Cited by 57
Adami, S., Rossini, M., Zamberlan, N., Bertoldo, F., Dorizzi, R., & Lo Cascio, V. (1993) · Maturitas · doi:10.1016/0378-5122(93)90046-k · Cited by 54
Lee, S.-J., Moye, L. A., Campos, H., Williams, G. H., & Sacks, F. M. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00007-8 · Cited by 50 · cited 1×
“Although insulin resistance is associated with high triglycerides, VLDL and triglyceride concentrations can be similar in patients with widely divergent insulin sensitivity (68, 69).”
Self-citationSacks, F. M. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.09.073 · Cited by 50
Self-citationKarpe, F. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00700-0 · Cited by 50 · cited 1×
“Remnants have been identified within human atherosclerosis plaques (145).”
McLaughlin, T., Abbasi, F., Lamendola, C. A., Yeni-Komshian, H., & Reaven, G. M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.9.6838 · Cited by 46 · cited 1×
“Acute or chronic elevation of insulin in response to a high carbohydrate diet did not lower serum triglyceride levels in healthy subjects (70, 71).”
Pitsavos, C., Panagiotakos, D. B., Tambalis, K. D., Chrysohoou, C., Sidossis, L. S., Skoumas, J., & Stefanadis, C. (2009) · QJM · doi:10.1093/qjmed/hcp083 · Cited by 45
Marcoux, C., Hopkins, P. N., Wang, T., Leary, E. T., Nakajima, K., Davignon, J., & Cohn, J. S. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33455-6 · Cited by 43
Fasting versus Nonfasting Triglycerides: Implications for Laboratory Measurements
Warnick, G. R., & Nakajima, K. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2007.098863 · Cited by 39 · cited 1×
“Further work is needed on determining the most informative procedure of collecting postprandial lipids and characterization of postprandial effects on triglyceride measurements (23).”
Young, S., Veniant, M., Beigneux, A., Bensadoun, A., & Fong, L. (2008) · Current Drug Targets · doi:10.2174/138945008783755629 · Cited by 33 · cited 1×
“A variety of animal models produced using dietary or genetic manipulations have confirmed that chylomicron remnants are atherogenic (139, 144).”
(2008) · PubMed · Cited by 32
Dekker, M. J., Graham, T. E., Ooi, T. C., & Robinson, L. E. (2010) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2009.08.004 · Cited by 32
Nonogaki, K., Moser, A. H., Feingold, K. R., & Grunfeld, C. (1994) · Endocrinology · doi:10.1210/endo.135.6.7988454 · Cited by 30 · cited 1×
“Hypertriglyceridemia in severe stress may be related to possible catecholamine induction of adipose tissue lipolysis and reduced LpL activity (102).”
Nakano, T., Tanaka, A., Okazaki, M., Tokita, Y., Nagamine, T., & Nakajima, K. (2011) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1258/acb.2010.010193 · Cited by 29
Severe hypertriglyceridemia and acute pancreatitis during pregnancy: treatment with gemfibrozil.
Saadi, H. F., Kurlander, D. J., Erkins, J. M., & Hoogwerf, B. J. (1999) · Endocrine Practice · doi:10.4158/ep.5.1.33 · Cited by 29 · cited 1×
“Gemfibrozil can be considered in very severe hypertriglyceridemia beginning in the second trimester in pregnant women who are at risk of pancreatitis (86).”
Exercise, postprandial triacylglyceridemia, and cardiovascular disease risk.
Graham, T. E. (2004) · Canadian Journal of Applied Physiology · doi:10.1139/h04-051 · Cited by 28
Impaired plasma lipid profiles in acute hepatitis.
Luo, L., Pu, X., Wang, Y., & Xu, N. (2010) · Lipids in Health and Disease · doi:10.1186/1476-511x-9-5 · Cited by 27 · cited 1×
“Acute hepatitis may be associated with increased VLDL production and hypertriglyceridemia (105).”
Prevalence of modifiable cardiovascular risk factors in German adolescents
Müller‐Riemenschneider, F., Nocon, M., & Willich, S. N. (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e328334703d · Cited by 26 · cited 1×
“levels in 20–25% of the participants (12, 13).”
Nakou, E. S., Filippatos, T. D., Agouridis, A. P., Kostara, C., Bairaktari, E. T., & Elisaf, M. S. (2010) · Lipids · doi:10.1007/s11745-010-3409-0 · Cited by 23
Carr, M. C., Knopp, R. H., Brunzell, J. D., Wheeler, B. S., Zhu, X., Lakshmanan, M., Rosen, A. S., & Anderson, P. W. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1555 · Cited by 22 · cited 1×
“derlying propensity to hypertriglyceridemia (89, 90).”
Self-citationPang, R. W. C., Tam, S., Janus, E. D., Siu, S. T. S., Ma, O. C. K., Lam, T. H., & Lam, K. S. L. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.05.013 · Cited by 20
Pancreatitis induced by oestrogen in a patient with type I hyperlipoproteinaemia.
Stuyt, P. M., Demacker, P. N., & Stalenhoef, A. F. (1986) · BMJ · doi:10.1136/bmj.293.6549.734 · Cited by 19 · cited 1×
“In patients with familial hypertriglyceridemia or LpL deficiency, the use of oral estrogens can provoke severe pancreatitis (109).”
Self-citationFurtado, J. D., Campos, H., Sumner, A. E., Appel, L. J., Carey, V. J., & Sacks, F. M. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28532 · Cited by 18 · cited 1×
“The OmniHeart study, in which 50% of the population was African-American, found that diet modification had less effect on triglyceride levels in this ethnic group than in a Caucasian population when matching baseline triglyceride levels (157).”
Self-citationMosca, L. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80127-2 · Cited by 18 · cited 1×
“derlying propensity to hypertriglyceridemia (89, 90).”
Enigmatic role of lipoprotein(a) in cardiovascular disease.
Anuurad, E., Enkhmaa, B., & Berglund, L. (2010) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2010.00238.x · Cited by 14
Self-citationGlitazones and the cardiovascular system.
Devchand, P. R. (2008) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e3282f79b20 · Cited by 12
Expression of type III hyperlipoproteinemia in an adolescent patient with hypothyroidism.
Lindner, M. A., & Illingworth, D. R. (1988) · The Journal of Pediatrics · doi:10.1016/s0022-3476(88)80536-5 · Cited by 10
Therapy of diabetes and dyslipidemia in acromegaly.
Tamburrano, G., Durante, C., & Baldelli, R. (2002) · Pituitary · doi:10.1023/a:1022101417810 · Cited by 9 · cited 1×
“LpL occurs in some acromegalic patients (84).”
Research works printed but not linked: 2
- Assmann, 1993, Results and conclusions of the prospective cardiovascular Munster (PROCAM) study, 19
- Brunzell, 2001, Familial lipoprotein lipase deficiency, ApoC-II deficiency, and hepatic lipase deficiency, 2789
Cited by
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Self-citationStone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Self-citation2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
“The definition of different categories for elevated fasting TG levels seems to be slightly variable in different guidelines and recommendations.(67,259) According to the EAS consensus document, mild to moderate HTG is defined as TGs .”
BackgroundDyslipidemia in obesity: Mechanisms and potential targets
Klop, B., Elte, J., & Cabezas, M. (2013) · Nutrients · doi:10.3390/nu5041218 · Cited by 1,665
“treatment targets next to LDL-C levels in the presence of the hypertriglyceridemic waist [11,136,138].”
Background2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Metadata
- Authors
- Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H.
- Affiliations
- University of California, Davis (US)
- University of Washington (US)
- Washington University in St. Louis (US)
- Columbia University (US)
- Harvard University (US)
- Mayo Clinic (US)
- Radboud University Medical Center (NL)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-09-01
- Volume
- 97
- Issue
- 9
- Pages
- 2969-2989
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC3431581
- OpenAlex
- W2111416524
- Cited by
- 887
- References
- 206
- Citations by year
- 2026: 55 · 2025: 54 · 2024: 74 · 2023: 62 · 2022: 72 · 2021: 74 · 2020: 83 · 2019: 61 · 2018: 89 · 2017: 50 · 2016: 62 · 2015: 57 · 2014: 48 · 2013: 41
- FWCI
- 47.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- American Heart Association
- European Society of Endocrinology
- National Heart, Lung, and Blood Institute (R01HL045095)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- hypertriglyceridemia, triglyceride levels, fasting triglycerides, cardiovascular risk, pancreatitis, secondary hyperlipidemia, familial hypertriglyceridemia, dyslipidemia, non-HDL cholesterol, lifestyle therapy, fibrate therapy
- MeSH terms
- Exercise Therapy, Humans, Terminology as Topic, Triglycerides, Hypertriglyceridemia, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.